Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes

[1]  Leonidas G Alexopoulos,et al.  COMBSecretomics: A pragmatic methodological framework for higher-order drug combination analysis using secretomics , 2020, PloS one.

[2]  Lori A. Dalton,et al.  High dimensional model representation of log-likelihood ratio: binary classification with expression data , 2020, BMC Bioinformatics.

[3]  M. Davies,et al.  AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis , 2019, Molecular Cancer Research.

[4]  J. Dopazo,et al.  Exploring the druggable space around the Fanconi anemia pathway using machine learning and mechanistic models , 2019, bioRxiv.

[5]  Xun Cai,et al.  Down‐regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion , 2018, Journal of cellular biochemistry.

[6]  Vasileios Stathias,et al.  Data Portal for the Library of Integrated Network-based Cellular Signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data , 2017, Nucleic Acids Res..

[7]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[8]  Jinguang Wang,et al.  Bioinformatics analysis of gene expression profiles to identify causal genes in luminal B2 breast cancer , 2017, Oncology letters.

[9]  W. Xia,et al.  MicroRNA-139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression , 2017, Oncology letters.

[10]  Qien Wang,et al.  High expression of Fibronectin 1 suppresses apoptosis through the NF-κB pathway and is associated with migration in nasopharyngeal carcinoma. , 2017, American journal of translational research.

[11]  R. He,et al.  Topical treatment of all‐trans retinoic acid inhibits murine melanoma partly by promoting CD8+ T‐cell immunity , 2017, Immunology.

[12]  E. Graner,et al.  Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas , 2017, Melanoma research.

[13]  Marion Vanneste,et al.  Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study , 2017, Oncotarget.

[14]  Man-Li Luo,et al.  miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. , 2017, Discovery medicine.

[15]  Yongkang Kim,et al.  Serum fibronectin distinguishes the early stages of hepatocellular carcinoma , 2017, Scientific Reports.

[16]  A. de la Chapelle,et al.  Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma , 2017, Proceedings of the National Academy of Sciences.

[17]  Philip R. O. Payne,et al.  Integrative network and transcriptomics-based approach predicts genotype- specific drug combinations for melanoma , 2017, AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.

[18]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[19]  Hao Jiang,et al.  MicroRNA-200c binding to FN1 suppresses the proliferation, migration and invasion of gastric cancer cells. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  F. Meric-Bernstam,et al.  A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC). , 2017 .

[21]  Chirag J Patel,et al.  A standard database for drug repositioning , 2017, Scientific Data.

[22]  Bo Mu,et al.  SATB1 plays an oncogenic role in esophageal cancer by up-regulation of FN1 and PDGFRB , 2017, Oncotarget.

[23]  S. Garattini,et al.  Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Kara Dolinski,et al.  The BioGRID interaction database: 2017 update , 2016, Nucleic Acids Res..

[25]  Minoru Kanehisa,et al.  KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..

[26]  M. Kozłowska-Wojciechowska,et al.  Drug Combinations as the New Standard for Melanoma Treatment , 2016, Current Treatment Options in Oncology.

[27]  Núria Queralt-Rosinach,et al.  DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants , 2016, Nucleic Acids Res..

[28]  Hongbo Shi,et al.  AKT1 as the PageRank hub gene is associated with melanoma and its functional annotation is highly related to the estrogen signaling pathway that may regulate the growth of melanoma. , 2016, Oncology reports.

[29]  Claudio Altafini,et al.  Drug combinatorics and side effect estimation on the signed human drug-target network , 2016, BMC Systems Biology.

[30]  Avi Ma'ayan,et al.  Drug-induced adverse events prediction with the LINCS L1000 data , 2016, Bioinform..

[31]  Madeleine Ennis,et al.  Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis , 2016, Proceedings of the National Academy of Sciences.

[32]  Michael Krauthammer,et al.  Integrated analysis of multidimensional omics data on cutaneous melanoma prognosis. , 2016, Genomics.

[33]  K. Brown,et al.  The genomic landscape of cutaneous melanoma , 2016, Pigment cell & melanoma research.

[34]  Q. Ge,et al.  Effects of acute intra-abdominal hypertension on multiple intestinal barrier functions in rats , 2016, Scientific Reports.

[35]  R. Dummer,et al.  The Genetic Evolution of Melanoma from Precursor Lesions. , 2015, The New England journal of medicine.

[36]  M. McMahon,et al.  AKT1 Activation Promotes Development of Melanoma Metastases. , 2015, Cell reports.

[37]  Sridhar Ramaswamy,et al.  Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment , 2015, PloS one.

[38]  Zhiwei Cao,et al.  Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer , 2015, Nature Communications.

[39]  Di Chen,et al.  Systematic synergy modeling: understanding drug synergy from a systems biology perspective , 2015, BMC Systems Biology.

[40]  Joel T Dudley,et al.  Mapping the effects of drugs on the immune system , 2015, Nature Biotechnology.

[41]  Nam Huh,et al.  Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway , 2015, Nature Genetics.

[42]  Karen A. Ryall,et al.  Systems biology approaches for advancing the discovery of effective drug combinations , 2015, Journal of Cheminformatics.

[43]  A. Rust,et al.  BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model , 2015, Proceedings of the National Academy of Sciences.

[44]  F. Filipp,et al.  Cancer systems biology of TCGA SKCM: Efficient detection of genomic drivers in melanoma , 2015, Scientific Reports.

[45]  Kern Rei Chng,et al.  Patient-specific driver gene prediction and risk assessment through integrated network analysis of cancer omics profiles , 2015, Nucleic acids research.

[46]  Chirayu Pankaj Goswami,et al.  PROGgeneV2: enhancements on the existing database , 2014, BMC Cancer.

[47]  J. Reifenrath,et al.  Different approaches for interpretation and reporting of immunohistochemistry analysis results in the bone tissue – a review , 2014, Diagnostic Pathology.

[48]  P. Sanseau,et al.  Systematic prediction of drug combinations based on clinical side-effects , 2014, Scientific Reports.

[49]  V. M. B. Grace,et al.  Anti-Metastatic Study of Liposome-Encapsulated All trans Retinoic Acid (ATRA) in B16F10 Melanoma Cells-Implanted C57BL/6 Mice , 2014, Cancer investigation.

[50]  Yang Xie,et al.  A community computational challenge to predict the activity of pairs of compounds Citation , 2015 .

[51]  B. Liu,et al.  Subcutaneous Adipocytes Promote Melanoma Cell Growth by Activating the Akt Signaling Pathway , 2014, The Journal of Biological Chemistry.

[52]  R. Scolyer,et al.  A novel hypoxia-associated subset of FN1highMITFlow melanoma cells: identification, characterization, and prognostic value , 2014, Modern Pathology.

[53]  Matthias E. Futschik,et al.  Targeting molecular networks for drug research , 2014, Front. Genet..

[54]  T. Graeber,et al.  COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors , 2014, Molecular oncology.

[55]  Chuan-Yuan Li,et al.  Caspase 3 promotes surviving melanoma tumor cell growth after cytotoxic therapy , 2014, The Journal of investigative dermatology.

[56]  Gwan-Su Yi,et al.  Drug Similarity Search Based on Combined Signatures in Gene Expression Profiles , 2014, Healthcare informatics research.

[57]  A. Butte,et al.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.

[58]  M. Ramanathan,et al.  Network‐Based Approaches in Drug Discovery and Early Development , 2013, Clinical pharmacology and therapeutics.

[59]  Damian Szklarczyk,et al.  STITCH 4: integration of protein–chemical interactions with user data , 2013, Nucleic Acids Res..

[60]  S. Gruber,et al.  Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. , 2013, The Journal of investigative dermatology.

[61]  Baocun Sun,et al.  Basal caspase-3 activity promotes migration, invasion, and vasculogenic mimicry formation of melanoma cells , 2013, Melanoma research.

[62]  Jihye Kim,et al.  Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer , 2013, Clinical Cancer Research.

[63]  J. Coebergh,et al.  Trends in the risks of melanoma as a second primary cancer among cancer patients in the Netherlands, 1989–2008 , 2013, Melanoma research.

[64]  Edward Y. Chen,et al.  Renoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase. , 2013, Journal of the American Society of Nephrology : JASN.

[65]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[66]  P. Sanseau,et al.  Computational Drug Repositioning: From Data to Therapeutics , 2013, Clinical pharmacology and therapeutics.

[67]  Saijuan Chen,et al.  8-CPT-cAMP/all-trans retinoic acid targets t(11;17) acute promyelocytic leukemia through enhanced cell differentiation and PLZF/RARα degradation , 2013, Proceedings of the National Academy of Sciences.

[68]  Jason A. Papin,et al.  Mechanistic systems modeling to guide drug discovery and development. , 2013, Drug discovery today.

[69]  M. Gore,et al.  Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. , 2013, Cancer discovery.

[70]  Pankaj Agarwal,et al.  Evaluation of Analytical Methods for Connectivity Map Data , 2012, Pacific Symposium on Biocomputing.

[71]  Kyoung Mii Park,et al.  CDA: Combinatorial Drug Discovery Using Transcriptional Response Modules , 2012, PloS one.

[72]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[73]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[74]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[75]  Jason A. Papin,et al.  Metabolic network analysis predicts efficacy of FDA-approved drugs targeting the causative agent of a neglected tropical disease , 2012, BMC Systems Biology.

[76]  E. White,et al.  Association of Vitamin A and Carotenoid Intake with Melanoma Risk in a Large Prospective Cohort , 2012, The Journal of investigative dermatology.

[77]  A. Bowcock,et al.  Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma , 2011, Clinical Cancer Research.

[78]  Xiang-Sun Zhang,et al.  Two-stage flux balance analysis of metabolic networks for drug target identification , 2011, BMC Systems Biology.

[79]  K. Smalley,et al.  Identification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis? , 2011, Expert review of anticancer therapy.

[80]  Christian Borgs,et al.  Finding undetected protein associations in cell signaling by belief propagation , 2010, Proceedings of the National Academy of Sciences.

[81]  Francesco Iorio,et al.  Identification of small molecules enhancing autophagic function from drug network analysis , 2010 .

[82]  Philip E. Bourne,et al.  Drug Off-Target Effects Predicted Using Structural Analysis in the Context of a Metabolic Network Model , 2010, PLoS Comput. Biol..

[83]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[84]  S. Friend,et al.  A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.

[85]  Jorge Cortes,et al.  Systems approaches and algorithms for discovery of combinatorial therapies. , 2009, Wiley interdisciplinary reviews. Systems biology and medicine.

[86]  P. Dahm,et al.  Reversal of Myeloid Cell–Mediated Immunosuppression in Patients with Metastatic Renal Cell Carcinoma , 2008, Clinical Cancer Research.

[87]  J. Idle,et al.  Role of Pregnane X Receptor in Control of All-Trans Retinoic Acid (ATRA) Metabolism and Its Potential Contribution to ATRA Resistance , 2008, Journal of Pharmacology and Experimental Therapeutics.

[88]  D. Soprano,et al.  Retinoids in biological control and cancer , 2007, Journal of cellular biochemistry.

[89]  R. Lotan,et al.  Decreased Expression of Retinoid Receptors in Melanoma: Entailment in Tumorigenesis and Prognosis , 2007, Clinical Cancer Research.

[90]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[91]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[92]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[93]  M. Martinka,et al.  Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[94]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[95]  R. Niles.  The use of retinoids in the prevention and treatment of skin cancer , 2002, Expert opinion on pharmacotherapy.

[96]  J. Hayes,et al.  Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice. , 1995, Cancer research.

[97]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[98]  Zhiyong Lu,et al.  A survey of current trends in computational drug repositioning , 2016, Briefings Bioinform..

[99]  Antoni Ribas,et al.  A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. , 2014, Cancer discovery.

[100]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[101]  Cynthia M. Lakon,et al.  How Correlated Are Network Centrality Measures? , 2008, Connections.

[102]  Fadlo R Khuri,et al.  Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. , 2006, Cancer research.